Browsing Tag

COMP360

COMPASS Pathways announces publication of positive data from treatment-resistant…

Eli Pacheco Jul 17, 2023 0

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of…

Health

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar…

Eli Pacheco Dec 8, 2022 0

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study…